Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib + PD-1 Blockade in Mucosal Melanoma
NCT05384496Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib in mucosal melanoma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started May 2022; status: recruiting.
02
Drugs
axitinib
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT05384496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384496.